In two import alerts posted in late March and early April, the FDA said all of Jiangsu Shenli’s piston syringes are subject to detention without physical examination.
The agency first raised issues with China-made plastic syringes in late November after receiving reports of the products breaking and leaking. During its investigation, Medline Industries and Sol-Millennium Medical received warning letters, and China-based Jiangsu Caina Medical Co. was cited for “unexpected and unexplained failures” with its syringes, the FDA said.
“We remain concerned that certain syringes manufactured in China may not provide consistent and adequate quality or performance,” the agency said April 10.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.